PROSTATIC CYTOPLASMIC ANDROGEN RECEPTOR IN PROSTATIC DISEASE : II. Correlation between Clinical Response to Hormonal Therapy and Change of R1881 Receptor Content in Prostatic Cancer During Antiandrogenic Therapy

1 Citations
  • Kitano Taiji
    Department of Urology, Hiroshima University School of Medicine

Bibliographic Information

Other Title
  • 前立腺細胞内アンドロジセェン レセプターについて.第2編.前立腺癌細胞内アンドロジェン レセプターと抗男性ホルモン療法の治療効果および治療の及ぼす影響について

Search this article

Description

Antiandrogenic therapy is the dominating form of treatment of prostatic carcinoma. The majority of cases are well controlled for varying periods with this regimen. However, there have been no adequate methods to predict in which cases antiandrogenic therapy is of less benefit. In this study, transurethral cold punch biopsies from 14 primary prostatic cancer patients were taken before antiandrogenic therapy was given, and the specimens were analyzed with regard to content of methyltrienolone (R1881) binding sites. Maximum binding capacity (Bmax) and dissociation constant (Kd) were calculated from Scatchard plots. To gain the change by which initial treatment of antiandrogenic therapy (diethylstilbestrol diphosphate 500mg/day, total 10g administered following bilateral orchiectomy) influences the regression of human prostatic adenocarcinoma, 9 in 14 patients were biopsied before and after treatment.

Journal

Citations (1)*help

See more

Details 詳細情報について

Report a problem

Back to top